Dendritic cell (antigen-presenting function in tumor immunity) (DC)

Dendritic cells are professional antigen-presenting cells that play a central role in initiating and regulating adaptive immune responses. They capture antigens—including those derived from tumors—process them into peptides, and present these peptides on major histocompatibility complex (MHC) molecules at their surface. This process activates naive T-cells within lymphoid organs, leading either to effective anti-tumor immunity or immune tolerance depending on context[6][8]. In cancer biology, "tumor-associated antigen presentation by dendritic cell" refers not to a single molecular entity but rather the process by which these specialized immune cells internalize tumor-derived proteins ("tumor-associated antigens"), process them via classical MHC class II pathways for CD4+ helper T-cell activation or cross-presentation via MHC class I pathways for cytotoxic CD8+ T-cell priming—a mechanism crucial for effective anti-tumor responses[2][4][5]. Dendritic cells exist as several subtypes—including conventional DCs (cDCs), plasmacytoid DCs (pDCs), and monocyte-derived inflammatory DCs—each contributing differently within the tumor microenvironment. Their abundance and functional state correlate with patient outcomes across multiple cancers; higher levels typically predict better survival due to more robust anti-tumor immunity[1][3]. However, this is not a canonical molecular drug target like an enzyme or receptor but rather describes an essential cellular function/process exploited therapeutically through vaccine development or adjuvant therapies designed to boost endogenous anti-tumor immunity. Note: The phrase "Tumor-associated antigen-presenting by dendritic cell" is not itself a standard name for any molecule/receptor but describes an important biological process carried out by the well-characterized immune cell type known as the **dendritic cell**. Therefore: - **is_incorrect:** true — This entry does not correspond directly to a single molecule/receptor/druggable protein but instead refers broadly to cellular activity/process. - For structured data purposes use “Dendritic cell” as canonical name; do not treat this phrase itself as a unique molecular entity.

Other names

Dendritic cellAntigen-presenting dendritic cellTumor-infiltrating dendritic cellProfessional antigen-presenting cell (APC)

Not applicable as a molecular drug target. However, therapeutic strategies aim to enhance the ability of dendritic cells to present tumor antigens and activate cytotoxic T-cells, often through ex vivo loading with tumor antigens or in vivo stimulation with cytokines such as GM-CSF[1][5].